Effect of ranolazine on improvement of heart function

Effect of Ranolazine on improvement of left ventricular dysfunction in patients with Chronic Stable Angina â?? a randomized controlled clinical trial. - EFFORT-LVR

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/01/004332

Enrollment

Registered

2014-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic stable angina

Interventions

Intervention1: Ranolazine: Ranolazine 500 mg BD orally for 8 weeks Control Intervention1: Trimetazidine: Trimetazidine 35 mg BD orally for 8 weeks

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who have sustained STEMI more than 12 weeks ago. 2.Left ventricular ejection fraction 3.Willing to give written informed consent and comply with all study related procedures

Exclusion criteria

Exclusion criteria: 1.h/o undergoing CABG or stenting procedure within the last 12 weeks. 2.Co-existing end-stage pulmonary, or hepatic disease 3.Valvular heart disease 4.Patient consumed other study medication in the last 3 months. 5.Unwilling to comply with study related procedures

Design outcomes

Primary

Measure	Time frame
Changes in LV systolic and diastolic function as assessed by transthoracic EchocardiographyTimepoint: Changes in LV systolic and diastolic function before after 8 weeks of treatment with study drug	—

Secondary

Measure	Time frame
1.Improvement in angina symptoms 2. ADRTimepoint: before and after 8 weeks of therapy	—

Countries

India

Contacts

Public ContactDr Melvin George

SRM Medical College Hospital

melvingeorge2003@gmail.com9894133697

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026